Results of a Validation Study in Germany on Two in Vitro Alternatives to the Draize Eye Irritation Test, the HET-CAM Test and the 3T3 NRU Cytotoxicity Test

1996 ◽  
Vol 24 (5) ◽  
pp. 741-858 ◽  
Author(s):  
Horst Spielmann ◽  
Manfred Liebsch ◽  
Sabine Kalweit ◽  
Ferdinand Moldenhauer ◽  
Tobias Wirnsberger ◽  
...  

During 1988–1992, a validation study was carried out in Germany on the capacity of two in vitro tests to replace the Draize eye test for severely eye irritating chemicals, namely, the hen's egg chorio-allantoic membrane (HET-CAM) test and the 3T3 cell neutral red uptake (NRU) cytotoxicity test, which had shown promising results in an earlier test development project. The formal validation study, which was coordinated by Centre for Documentation and Evaluation of Alternative Methods to Animal Experiments (ZEBET) and funded by the German Department of Research and Technology (BMBF), was conducted in two phases: Phase I consisted of a prevalidation study and a blind trial (1988–1990); and Phase II was the database development phase (1991/1992). During prevalidation, the two in vitro tests were established in 13 laboratories, standard protocols were developed, including PC-based software programs for data recording, and 34 chemicals backed by high quality literature data were selected for the ring trial. In the 1-year ring trial, the two in vitro tests were validated with 34 coded chemicals under blind conditions in 13 laboratories, to evaluate the reproducibility of the two tests within and among laboratories. In the blind trial, the 3T3 NRU cytotoxicity test showed a better reproducibility than the HET-CAM test, but compared to the cytotoxicity test, the HET-CAM test permitted a significantly better classification of severely eye irritating chemicals, which are labelled R41 according to EU regulations. Since it was recommended in 1990 by the first Amden validation workshop that a database of around 200 chemicals is required for the assessment of test performance to reach regulatory acceptance at the international level, a 2-year database development was conducted as Phase II, during which 166 coded chemicals were tested in the two in vitro tests, each of them in two laboratories. Test chemicals backed by high-quality Draize eye test data were provided by industry and selected to represent a wide spectrum of chemical classes and eye irritation properties. Independent quality control of in vitro and in vivo data and biostatistical evaluation were performed during an additional BMBF project on biostatistics. In the quality assurance step, which is an essential prerequisite for biostatistics, the number of chemicals was reduced to 143, and these data were entered into an MS-EXCEL database to facilitate determination of in vitro/in vivo correlations. Unexpectedly, the evaluation of the study had to take into account a change of criteria within the EU for classifying severely eye irritating chemicals as R41, since irreversible damage within a 21-day observation period was introduced as a new criterion for R41 chemicals. The results of the 3T3 NRU cytotoxicity test showed an insufficient in vitro/in vivo correlation for classifying R41 chemicals. Classification of HET-CAM data was also insufficient in the Bundesgesundhütsamt (BGA) scoring system, which uses an empirically developed weighted scoring of the three endpoints, namely, haemorrhage, lysis and coagulation. Discriminant analysis of ten endpoints routinely determined in the HET-CAM test and in the 3T3 NRU cytotoxicity test revealed that the detection time of coagulation, the most severe reaction on the CAM, was significantly better suited to identifying severely eye irritating properties than any other endpoint, and better than the BGA score for the HET-CAM test. For water-soluble chemicals (mean time for detection of coagulation [mtc]10), the detection time for coagulation of a 10% solution had the highest discriminant power, and for less water-soluble chemicals (mtc100), the detection time of coagulation of the undiluted chemical was more appropriate. Discriminant analysis of the combination of mtc10 and mtc100 with other endpoints of the two in vitro tests revealed that classification of water-soluble chemicals is significantly improved by combining mtc10 and lgfg50m (logarithm of IC50 value calculated with the Fit-Graph program), the endpoint of the 3T3 NRU cytotoxicity test. Further analysis of data from Phase I and Phase II of the study demonstrated that chemicals characterised by an mtc10 of < 50 seconds can be labelled R41 without any false positive classifications. By using this cut-off point, around 25% of R41 chemicals can be classified without further testing in vitro or in vivo. Classification was further improved when solubility in water and oil was taken into account. The best classification of water-soluble R41 chemicals (> 10%) was obtained when the mtc10 of the HET-CAM test and the lgfg50m of the 3T3 NRU cytotoxicity test were combined. For chemicals soluble in oil (> 10%) and for insoluble chemicals, the mtc100 provided the best classification. The in vitro classification results were confirmed by cross-validation. These promising results allowed a sequential approach to be developed for classifying severely eye irritating chemicals as R41 according to EU regulations by combining the HET-CAM test and the 3T3 NRU cytotoxicity test results. The present study suggests that severely eye irritating chemicals can be classified as R41 with a sufficiently high level of confidence with the two in vitro tests, since the percentage of false positive and false negative results are kept within an acceptably low range. Thus, the combined use of the HET-CAM test and the 3T3 NRU cytotoxicity test meets the requirements for “well-validated” tests, as defined in the escape clause of OECD Guideline 405 for eye irritation testing.

2020 ◽  
Author(s):  
Miguel O Jara ◽  
Zachary N Warnken ◽  
Robert O Williams

We developed an amorphous solid dispersion (ASD) of the poorly water soluble molecule niclosamide that achieved more than a 2 fold increase in bioavailability. Notably, this niclosamide ASD formulation increased the apparent drug solubility about 60 fold relative to the crystalline material due to the generation of nanoparticles. Niclosamide is a weakly acidic drug, BCS class II, and a poor glass former with low bioavailability in vivo. Hot melt extrusion is a high throughput manufacturing method commonly used in the development of ASDs for increasing the apparent solubility and bioavailability of poorly water-soluble compounds. We utilized the polymer polyvinylpyrrolidone vinyl acetate (PVPVA) to manufacture niclosamide ASDs by extrusion. Samples were analyzed based on their microscopic and macroscopic behavior and their intermolecular interactions, using DSC, XRD, NMR, FTIR, and DLS. The niclosamide ASD generated nanoparticles with a mean particle size of about 100 nm in FaSSIF media. In a side by side diffusion test, these nanoparticles produced a 4 fold increase in niclosamide diffusion. We successfully manufactured amorphous extrudates of the poor glass former niclosamide that showed remarkable in vitro dissolution and diffusion performance. These in vitro tests were translated to a rat model that also showed an increase in oral bioavailability.


Pharmaceutics ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 365 ◽  
Author(s):  
Heejun Park ◽  
Eun-Sol Ha ◽  
Min-Soo Kim

Self-emulsifying drug delivery systems (SEDDSs) are a vital strategy to enhance the bioavailability (BA) of formulations of poorly water-soluble compounds. However, these formulations have certain limitations, including in vivo drug precipitation, poor in vitro in vivo correlation due to a lack of predictive in vitro tests, issues in handling of liquid formulation, and physico-chemical instability of drug and/or vehicle components. To overcome these limitations, which restrict the potential usage of such systems, the supersaturable SEDDSs (su-SEDDSs) have gained attention based on the fact that the inclusion of precipitation inhibitors (PIs) within SEDDSs helps maintain drug supersaturation after dispersion and digestion in the gastrointestinal tract. This improves the BA of drugs and reduces the variability of exposure. In addition, the formulation of solid su-SEDDSs has helped to overcome disadvantages of liquid or capsule dosage form. This review article discusses, in detail, the current status of su-SEDDSs that overcome the limitations of conventional SEDDSs. It discusses the definition and range of su-SEDDSs, the principle mechanisms underlying precipitation inhibition and enhanced in vivo absorption, drug application cases, biorelevance in vitro digestion models, and the development of liquid su-SEDDSs to solid dosage forms. This review also describes the effects of various physiological factors and the potential interactions between PIs and lipid, lipase or lipid digested products on the in vivo performance of su-SEDDSs. In particular, several considerations relating to the properties of PIs are discussed from various perspectives.


1990 ◽  
Vol 17 (3) ◽  
pp. 255-262
Author(s):  
Guido A. Jacobs ◽  
Mark A. Martens

Measurement of corneal swelling is an objective assessment of irritation in in vivo tests. The same measurement may be made in in vitro tests using the isolated eye test (IET), which has been recommended by the European Community as an alternative for in vivo eye irritation tests. In order to compare the corneal swelling in vivo and in vitro, tests were performed with 34 substances. The in vitro test results were assessed for their ability to predict eye-irritant potential. The corneal swelling data in vivo after 4, 24, 48 and 72 hours were compared with the in vitro data obtained after 2 and 4 hours. Slight linear correlation was found between the corneal swelling in vivo after 4 hours and the corneal swelling in vitro after 4 hours (r=0.77). The substances tested can be divided into two groups, according to their ability to create opacity in either the epithelial layer or in the stroma. When the substances causing epithelial opacity were omitted from the comparison, a much better linear correlation was obtained between the mean corneal swelling 121 vitro over 2 and 4 hours and the mean corneal swelling calculated in vivo for all animals and over three observation times (24, 48 and 72 hours; r=0.91), the latter being the observation times prescribed by EC legislation (1). A comparison of the mean corneal opacity scores observed in vivo and the mean percentage corneal swelling in vitro gave a satisfactory linear correlation (r=0.89). From this study it can be deduced that a mean corneal swelling of 55%, obtained in isolated eyes over 2 and 4 hours, corresponds with the limit for classification as irritant, to the eye. When this criterion was applied to all substances causing no epithelial opacity (n=28), only one false positive and no false negatives were found.


1993 ◽  
Vol 9 (6) ◽  
pp. 1017-1025 ◽  
Author(s):  
Ih Chu ◽  
Peter Toft

The rabbit eye irritation test based on the Draize method is required for the hazard assessment of chemicals and products that may come into contact with the eye. Due to the potential for the suffering of animals and subjectivity of the test, many modifications of the method have been made that involved a reduction in the number of animals and a refinement of techniques. Additionally, there has been significant development of in vitro alternatives. This paper reviews recent advances in the in vivo test and in vitro alternatives, as well as regulatory requirements. While the refinement of in vivo protocols has resulted in a reduction in the number and discomfort on animals, the development of in vitro alternatives could lead to an eventual replacement of animal studies. In view of the inherent simplicity of many in vitro methods, some of which comprise cell cultures, further research into the relevance/mechanism of effects is required. Batteries of in vitro tests, when properly validated, may be considered as replacements for animal testing.


Author(s):  
Robert Williams III ◽  
Zachary Warnken ◽  
Miguel Jara

We developed an amorphous solid dispersion (ASD) of the poorly water-soluble molecule niclosamide that achieved more than a 2-fold increase in bioavailability. Notably, this niclosamide ASD formulation increased the apparent drug solubility about 60-fold relative to the crystalline material due to the generation of nanoparticles. Niclosamide is a weakly acidic drug, BCS class II, and a poor glass former with low bioavailability in vivo. Hot-melt extrusion is a high-throughput manufacturing method commonly used in the development of ASDs for increasing the apparent solubility and bioavailability of poorly water-soluble compounds. We utilized the polymer polyvinylpyrrolidone&ndash;vinyl acetate (PVP&ndash;VA) to manufacture niclosamide ASDs by extrusion. Samples were analyzed based on their microscopic and macroscopic behavior and their intermolecular interactions, using DSC, XRD, NMR, FTIR, and DLS. The niclosamide ASD generated nanoparticles with a mean particle size of about 100 nm in FaSSIF media. In a side-by-side diffusion test, these nanoparticles produced a 4-fold increase in niclosamide diffusion. We successfully manufactured amorphous extrudates of the poor glass former niclosamide that showed remarkable in vitro dissolution and diffusion performance. These in vitro tests were translated to a rat model that also showed an increase in oral bioavailability.


Author(s):  
MUTHADI RADHIKA REDDY ◽  
KUMAR SHIVA GUBBIYAPPA

Lipid-based drug delivery systems are extensively reported in the literature for enhancing drug solubility, permeability, and bioavailability. Self-nanoemulsifying drug delivery systems (SNEDDS) are a superior strategy for enhancing solubility and bioavailability of poorly water-soluble compounds and the most prevailing and commercially viable oil-based approach for drugs that exhibit low dissolution rate and inadequate absorption. However, these formulations have few limitations that include in vivo drug precipitation, inferior in vitro in vivo correlation owing to unavailability of in vitro tests, handling issues of liquid formulation, and physicochemical instability of drugs. These limitations are overcome by potential systems such as supersaturable SNEDDS (S-SNEDDS) which are prepared by addition of precipitation inhibitors into formulated SNEDDS to maintain drug supersaturation post dispersion in gastrointestinal tract. These systems improve drug bioavailability and reduce the inconsistency of exposure. In addition, these formulations also help to overcome the drawbacks of liquid and capsule dosage forms. The S-SNEDDS provides an effective approach for improving the dissolution and bioavailability of anti-cancer agents. In this article, an attempt was made to present an overview of SNEDDS, S-SNEDDS, their mechanism, formulation excipients, recent advancements, advantages, and disadvantages of SNEDDS formulations. The article also focuses on reviewing the application of S-SNEDDS in enhancing the solubility and bioavailability of anti-cancer drugs in cancer therapy.


2010 ◽  
Vol 38 (4) ◽  
pp. 303-314 ◽  
Author(s):  
Yang Ying ◽  
Yang Xingfen ◽  
Zhang Wengai ◽  
Cai Jinheng ◽  
Xue Jinyu ◽  
...  

2008 ◽  
Vol 36 (1) ◽  
pp. 81-92 ◽  
Author(s):  
Christina Grindon ◽  
Robert Combes ◽  
Mark T.D. Cronin ◽  
David W. Roberts ◽  
John F. Garrod

This paper presents some results of a joint research project, sponsored by Defra and conducted by FRAME and Liverpool John Moores University, on the status of alternatives to animal testing with regard to the European Union REACH (Registration, Evaluation and Authorisation of Chemicals) system for the safety testing and risk assessment of chemicals. The project covered all the main toxicity endpoints associated with REACH. This paper focuses on the use of alternative (non-animal) methods (both in vitro and in silico) for eye irritation testing. The manuscript reviews numerous in vitro tests and their possible collation into test batteries, in silico models and a refined in vivo method (the low volume eye test), before combining the use of all these methods into an integrated testing strategy. The aim of this strategy is a reduction in the number of animal tests which would need to be performed in the process of fulfilling the REACH system criteria; this would also lead to a lowering of the number of animals required in compliance with the REACH system requirements.


RSC Advances ◽  
2016 ◽  
Vol 6 (21) ◽  
pp. 17074-17082 ◽  
Author(s):  
Jian-Qiang Zhang ◽  
Ke Li ◽  
Kun-Ming Jiang ◽  
Yan-Wei Cong ◽  
Shao-Ping Pu ◽  
...  

A novel water-soluble oral satraplatin/β-cyclodextrin inclusion complex was prepared and characterized with a variety of techniques. The inclusion complex showed much higher antitumor activity in vitro cytotoxicity test and in vivo antitumor test.


2008 ◽  
Vol 36 (1_suppl) ◽  
pp. 111-122 ◽  
Author(s):  
Christina Grindon ◽  
Robert Combes ◽  
Mark T.D. Cronin ◽  
David W. Roberts ◽  
John F. Garrod

This paper presents some results of a joint research project, sponsored by Defra and conducted by FRAME and Liverpool John Moores University, on the status of alternatives to animal testing with regard to the European Union REACH (Registration, Evaluation and Authorisation of Chemicals) system for the safety testing and risk assessment of chemicals. The project covered all the main toxicity endpoints associated with REACH. This paper focuses on the use of alternative (non-animal) methods (both in vitro and in silico) for eye irritation testing. The manuscript reviews numerous in vitro tests and their possible collation into test batteries, in silico models and a refined in vivo method (the low volume eye test), before combining the use of all these methods into an integrated testing strategy. The aim of this strategy is a reduction in the number of animal tests which would need to be performed in the process of fulfilling the REACH system criteria; this would also lead to a lowering of the number of animals required in compliance with the REACH system requirements.


Sign in / Sign up

Export Citation Format

Share Document